Skip to main content

Advertisement

Table 5 Bleeding cases by dabigatran dose and each factor

From: Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration

Factor Bleeding (+) (n = 57) Bleeding (−) (n = 644) ODDS ratio [95% CI], (P-value)
Very low-dose (75 mg twice daily) 3 23 1.50 [0.44–5.16], (0.520)
Age, years 74.0 ± 9.0 70.9 ± 11.0 1.03 [1.00–1.06], (0.036*)
Gender, female 19 225 1.07 [0.60–1.90], (0.808)
Creatinine clearance: Ccr (mL/min) 61.6 ± 29.4 69.4 ± 24.9 0.99 [0.97–1.01], (0.038*)
History of bleeding 9 70 1.53 [0.72–3.27], (0.264)
New users 19 335 0.46 [0.26–0.82], (0.007*)
Change from warfarin 26 206 1.81 [1.05–3.12], (0.034*)
C: Congestive heart failure 12 126 1.01 [0.51–1.96], (0.987)
H: Hypertension 38 388 0.76 [0.42–1.39], (0.376)
A: Aged 75 or older 33 261 1.78 [1.02–3.10], (0.043*)
D: Diabetes Mellitus 9 131 0.67 [0.32–1.39], (0.282)
S: Stroke/TIA (2 points) 24 161 2.00 [1.15–3.51], (0.015*)
CHADS2 score 2.44 ± 1.34 1.90 ± 1.34 1.33 [1.09–1.61], (0.005*)
With antiplatelet agents 17 112 2.02 [1.10–3.69], (0.022*)
  1. *P < 0.056